Clinical Trials Logo

Filter by:
NCT ID: NCT06375382 Completed - Crohn Disease Clinical Trials

Effects of Acupuncture on Abdominal Pain-related Intestinal Flora in Patients With Crohn's Disease

Start date: March 1, 2015
Phase: N/A
Study type: Interventional

Crohn's disease is an intestinal inflammatory disease, causing abdominal pain, diarrhea and other symptoms. The intestinal flora disorder is closely related to the occurrence and development of Crohn's disease. Acupuncture can induce remission of Crohn's disease during mild to moderate active period, improve clinical symptoms such as abdominal pain. This study is to screen the intestinal bacteria related to abdominal pain in CD, and explore the effects of acupuncture on the intestinal flora related to abdominal pain in CD patients.

NCT ID: NCT06375161 Recruiting - B Cell Malignancies Clinical Trials

Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.

Start date: December 11, 2023
Phase: Early Phase 1
Study type: Interventional

This study is a single-center, open-label, single-dose clinical trial of anti-CD19-CAR-T cell therapy in relapsed/refractory B-cell tumor patients after Qinglin pre-treatment. In this study phase, a traditional "3+3" trial design is employed for dose escalation.

NCT ID: NCT06375148 Enrolling by invitation - Enteral Nutrition Clinical Trials

A Questionnaire Survey on Cognition of Enteral Nutrition Implementation in Patients Requiring Mechanical Ventilation in Prone Position

Start date: March 20, 2024
Phase:
Study type: Observational

Prone ventilation is an important treatment for respiratory failure with intractable hypoxia, and the Corona Virus Disease 2019(COVID-19 ) outbreak has further elevated the status of prone ventilation. Early enteral nutrition (EN) is also recognised as an important measure to improve the prognosis of critically ill patients. However, the administration of enteral nutrition during prone position is still quite controversial. In this paper, we analysed the tolerance and safety of enteral nutrition in the prone position by reviewing studies before and after the COVID-19 outbreak. Key strategies to improve the tolerability of enteral nutrition in the prone position are also summarised and discussed.

NCT ID: NCT06375044 Recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Start date: May 24, 2024
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial.

NCT ID: NCT06375031 Recruiting - Diabetes Clinical Trials

Comparison of HR011408 and NovoRapid® in Subjects With Diabetics

Start date: May 2024
Phase: Phase 1
Study type: Interventional

The objective of the study is to compare the pharmacokinetics and pharmacodynamics between HR011408 and NovoRapid® in Subjects with Diabetics.

NCT ID: NCT06375005 Not yet recruiting - Clinical trials for Diffuse Cutaneous Systemic Sclerosis

Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

This study is a prospective, open-label, randomized, controlled, multi-center clinical trial. The aim of this study is to investigate the efficacy and safety of Telitacicept in adults with early diffuse cutaneous systemic sclerosis (dcSSc), with Mycophenolate Mofetil (MMF) administered as a background treatment.

NCT ID: NCT06374966 Not yet recruiting - Epilepsies, Partial Clinical Trials

Real-world Study of Efficacy and Safety of Zonisamide in add-on Therapy for Patients With Focal Epilepsy

Start date: April 2024
Phase:
Study type: Observational

Patients were first observed for a 4-week baseline period, which required no medication adjustments and a seizure frequency of greater than or equal to 2 times per 4-week . After the baseline observation period, if the patients met the criteria for enrolment and there were no contraindications, zonisamide was added as an additional therapeutic drug.Clinical data were collected before the initiation of treatment, at 1 month, 3 months and 6 months after taking zonisamide respectively, with regular review of blood tests and urinary ultrasound, and imaging and electrophysiological examinations according to the clinical needs of the patient's actual condition.

NCT ID: NCT06374953 Recruiting - Hyperfibrinolysis Clinical Trials

A Novel Viscoelastic Test Based on Ultrasonic Guided Wave for Identifying Hyperfibrinolysis Rapidly

Start date: March 26, 2024
Phase:
Study type: Observational

This study compares the results of the existing fibrinolysis monitoring technology to the Ultrasound-based viscoelastic hemostasis analysis, a new method, using small amount of extra blood obtained during routine blood draws in surgery patients.

NCT ID: NCT06374901 Not yet recruiting - Gastric Cancer Clinical Trials

Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.

Start date: April 25, 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of Tislelizumab in combination with chemotherapy versus chemotherapy in neoadjuvant treatment of patients with MHC-II positive (IHC≥2+) and locally advanced gastric/gastroesophageal junction adenocarcinoma by evaluating the main pathologic response rate (MPR).

NCT ID: NCT06374823 Not yet recruiting - Critical Care Clinical Trials

Multiple Electrolytes Injection (II) and Normal Saline on Hyperchloremia in Severe Hemorrhagic Stroke

MERIT
Start date: May 2024
Phase: Phase 4
Study type: Interventional

Normal saline (0.9% sodium chloride), a classical crystalloid solution, is widely used to maintain fluid balance, volume resuscitation and dilute drugs during clinical practice. However, the chloride concentration of normal saline (154mmol/L) is much higher than human plasma, and a large amount of infusion may lead to iatrogenic hyperchloremia in ICU patients. In contrast, the concentrations of Multiple electrolytes II is more similar to those of plasma and is considered to be a better fluid choice than normal saline.